I am delighted to share that on March 17, 2026, the United States Patent and Trademark Office officially issued U.S. Patent No. 12,576,160 for our technology, “Bispecific bridge nanoparticles for efficient targeting of cancer cells using immunotherapy (universal CAR-T cells) or chemotherapeutic” (Notre Dame docket P21-043-US01). This is the same invention that received its Notice …
Tag Archive: cancercure
NIH Funding Opportunities
- Notice to Rescind NOT-HL-24-008 "NHLBI Announces New Policies Regarding Budget Guidelines for SBIR/STTR Applications" May 13, 2026Notice NOT-HL-26-005 from the NIH Guide for Grants and Contracts
- Notice of Early Expiration of PAR-25-202 "Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)" May 12, 2026Notice NOT-GM-26-005 from the NIH Guide for Grants and Contracts
Recent Comments